Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Hypertension. 2010 Oct 18;56(6):1131–1136. doi: 10.1161/HYPERTENSIONAHA.110.160481

Table 3.

Multivariate-adjusted model of the association between log-transformed urinary cGMP/Cr and VEGF inhibitor

Covariates included in model β Coefficient for VEGF inhibitor use p value for VEGF inhibitor use
VEGF inhibitor use −0.30 0.018
VEGF inhibitor use + age −0.30 0.014
VEGF inhibitor use, age, prior HTN, ACE-inhibitor −0.32 0.013
VEGF inhibitor use, age, prior HTN, ACE-inhibitor, nephrectomy −0.24 0.047

cGMP/Cr denotes cyclic GMP:creatinine ratio; VEGF, vascular endothelial growth factor; HTN, hypertension; ACE, angiotensin-converting enzyme